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Lipoxin A. and lipoxin B4 are newly discovered lipoxygenase-interacting products of leukocytes which might have a role 
in cardiovascular events associated with anaphylaxis. We have tested this possibility by systemic administration of both 
LXA. and LXB4 to the conscious rat while monitaring systemic and regional hemodynamic changes. LXA. and' LXB4 
(l-100 pgfkg) produced dose-dependent constriction of the mesenteric vessels, up to + 123±23% and +50±9% for 
LXA./B4 , respectively. Dose-related changes were not observed in arterial blood pressure, heart rate, renal (LXB4) and 
hindquarter blood ftow. We suggest that LXA. and LXB4 might affect selective vascular beds, such as the mesenteric 
vessels, and contribute to variations in blood flow in specific pathophysiological states. 
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1. INTRODUCTION 
Lipoxin A (LXA.) and lipoxin B4 (LXB4) are 
lipoxygenase-interacting products of the following 
respective structure: 5S,6R, 158-trihydroxy-7 ,9, 13-
trans-11-cis-eicosatetraenoic acid and 5S,14R,l5S-
trihydroxy- 6,1 0,12- trans- 8- cis- eicosatetraenoic 
acid [1-3]. LXA. is produced by activated eosino-
phil leukocytes [4] and L~ and LXB4 by poly-
morphonuclear (PMN) leukocytes [5]. L~ was 
shown to induce neutrophil chemotaxis, super-
oxide production, contraction of guinea pig lung 
strips, arteriolar dilation in the hamster cheek 
pouch vessels and rat glomerular afferent arterio-
les [5]. Furthermore, LXA. and LXB4 were shown 
to inhibit NK-cell activity [3]. Of special interest 
are recent sturlies showing activation of protein 
kinase C by LXA. [6] suggesting an intracellular 
role in signal transduction. 
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While these data support a biological role for 
L~ and LXB4 in multiple organs and systems, 
little information is available on the discrete ac-
tions of lipoxins on blood vessel tonein vivo. The 
potential modulation by LXA. and LXB4 of organ 
blood flow might be of special interest, since L~ 
is generated by activated eosinophils, which are the 
source of massive production and release of 
eicosanoids in acute systemic anaphylaxis. In this 
latter reaction, we have recently shown a marked 
decrease in splanchnic organ blood flow which per-
sisted beyond the systemic hypotension [7]. A 
systematic search for the potential arachidonate 
mediator(s) of blood flow derangements in acute 
anaphylaxis yielded only partial information in-
dicating that cysteinyl-leukotrienes (L TC4/04/E.) 
might be involved in the prolonged mesenteric 
vasoconstriction [8]. Yet other lipoxygenase 
products of arachidonate might play a role in this 
shock syndrome since L Ts cannot reproduce all the 
hemodynamic responses of acute anaphylaxis nor 
can 5-lipoxygenase inhibitors completely reverse 
these phenomena [9]. · 
The discovery and further availability of pure 
synthetic LXA4 and LXB4 prompted us to examine 
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Table 1 
Baseline Ievels of hemodynamic variables before LXA. and LXI4 administration in the conscious rat 
Group MAP HR. Blood flow (kHz) Resistance (mmHglkHz) 
(mmHg) (bpm) 
HQ R M HQ R M 
Vehicle i. v. 124 ± s 395 ± 14 6.3 ± 0.9 6.2 ± 0.7 6.1 ± 0.8 25 ± 7 19 ± 2 21 ± 3 
LXA. i.v. 123 ± 5 390 ±·14 6.4 ± 0.9. 6.5 ±~ 0.8. 7.0 ± 0.6 24 ± 6 19 ± 2 18 ± 1 
LXB4 i.v. 119 ± 8 380 ± 15 6.2 ± 1 6.9 ± 0.6 7.1 ± 0.9 25 ± 7 18 ± I 18 ± 3 
MAP I mean arterial pressure; HR. heart rate; bpm •. beats per min; HQ, hindquarter; R, renal; M, mesenteric 
2. MATERIALS AND METHODS whether LXA. or LXB4 can produce the type of 
mesenteric, · renal and hindqu~er· circulatory 
changes produced .bY acute systemic, anaphylaxis. 
Male Sprague-Dawley rats (275-300 g, Taconic Farms, Ger-
mantown, NY) were anesthetized with an intramuscular injec-
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Fig.l., Effeet of LXA. on systemic and: regional hemodynamic variables in the conscious rat. Black columns rcpresent the effect of 
the vehicle injection while blank colurims represent the vatiaus doses of LXA-4 from l to 100 pg/ka (abscissa). DJe.d VR, percent change 
in vascular re5istance; IJoABF, percerit change in blOod flow for the respeetive organ; ·.dMAP, change in mean arterial pressure; .dHR, 
change in heart rate; N, number of rats studied. Asterisks represent statistical significance by AN OVA followed by Student-Newman-
Keul test as indicated in the figure. 
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tion of ketamine (130 mg/kg) and aceprornazine (1.3 mg/kg) 
and Doppler flow probes implanted on the left renal artery, 
superior mesenteric .. artery and the lower abdominal aorta, 
through a mid-laparotomy incision [10]. The rats were allowed 
to recover for S-7 day.s. 24 h prior to the experiment the rats 
were anesthetized again (20fo halothane in oxygen) and PE-SO 
tubing inseJ,1ed ipto the left femoral artery and vein. The 
cathethers were threaded under the back skin, exited at the nape 
and further secured by an adhesive collar and spring-wire [11]. 
The Dopper flow probes were connected to a directional pulsed 
Doppler flowmeter (model n'o.S4Sc-3, University of lowa 
Bioengineering Facility) and the arterialline to a blood pressure 
transducer (Narco RPlSOOi). Mean arterial blood pressure 
(MAP) and heart rate as well as renal, mesenteric and hind-
quarter blood flow (RBF, MBF, HQBF, respectively) were con-
tinuously monitored by the computerized Narcotrace 80 
physiograph. Changes in regional vascular resistance were 
calculated by dividing the change in ~ by the change in the 
regional bl~ flow. 
Followmg3Q-60 ~ of baseline recording for all. the above 
mentioned parameters, LXA. or LXB.. were' injected 
systemically in a bolus of 1SO ,ul volume, in ascending doses of 
3, 10, 30 and 100 ,ug/kg while allowing 30 min for complete 
recovery between injections. 
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Pure synthetic LXA. and LXB.. were purchased from 
Biomol, Philadelphia, PA. Stock solutions of LXA.. and LXB .. 
were kept in ethanol under argon. Sampies to be used were 
evaporated undcr an argon stream to a volume of S ,ul and fur-
ther diluted by 145 ,ul of 0.90fo NaCl solution (sterile, pyrogen 
free) for immediate systcmic injections. At no time were diluted 
samples of LXA.. and LXS.. re-frozen nor were they kept at 
room temperature beyond the few minutes necessary for 
preparation for injection. 
The data in text and figures represent mean ± SE for the in-
dicated number of rats. ANOVA followed by the Student-
Newman-Keul test for multiple comparisons was used for 
statistical analysis of the data andp < O.OS accepted as a signifi-
cant value. 
3. RESULTS 
Table 1 shows the basal systemic and regional 
heinodynamic indices of the rats. The data indicate 
no significant effect of the vehicle solution (5 ,ul 
ethanol and 145 ,ul of 0.90Jo NaCl) on any of the 
hemodynamic variables. 
Figs 1 and 2 show the hemodynamic effects of 
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Fig.2. Effect of LX~ on systemic and regional hemodynamic variables in the conscious rat. All symbols are explained in the legend 
to fig.l. 
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various doses of LX~ and LXB4. LX~ and 
LXB4 at the doses of 10 and 30 ,ug/kg induced a 
slight increase in MAP with no significant changes 
in heart rate. The higher doses of either L~ or 
LXB4 produced mesenteric vasoconstriction which 
resulted in reduction of MBF. L~ at the highest 
doses also slightly increased RVR, but LXA4 and 
LXB4 had no effect on HQBF. All the lipoxin-
induced cardiovascular changes reached their max-
imum 30 s after the injection and subsided in 
2-3 min. 
4. DISCUSSION 
The data reported here clearly show that both 
lipoxin ~ and lipoxin B4 possess significant 
vasoconstrictor activity on the mesenteric vessels 
of the rat when administered in i. v. bolus injec-
tions. The constriction of the mesenteric vessels by 
LX~ and LXB4 resulted in decreased blood flow 
which was not accompanied by any significant 
changes of blood pressure or heart rate. Therefore, 
the vascular changes most probably reflect a direct 
action on the given blood vessels. LXB4 had no 
significant effects on the renal or hindquarter 
vascular tone while LX~ also produced a signifi-
cant increase in renal vascular resistance. The con-
tractile nature of LX~ and LXB4 on the 
mesenteric vessels is similar in potency to the 
spasmogenic effect of LX~ in the guinea pig lung 
strips [12]. In the only two studies available so far 
in which vascular smooth muscle responses were 
examined, L~ produced vasodilation. In one 
case, L~ produced arteriolar dilation of the 
hamster cheek pouch vessels when added topically 
to the cheek pouch [12]. In the second case, selec-
tive reduction in the afferent renal arteriolar 
resistance to LX~ was seen during intra-renal 
arterial administration at a dose of 750 ng/kg per 
min at a rate of 25 ,ul/min for approx. 25 min [13]. 
The studies reported here are therefore in contrast 
to previously reported vascular effects of lipoxins. 
The effects of L~ and LXB4 demonstrated in 
this model are also substantially different from 
those of the cysteinyl-leukotrienes. Low doses 
(0.1-1 pg/kg) of leukotrienes D4/~ produced 
short Iasting vasodilation of hindquarter blood 
vessels, mesenteric constriction and change in renal 
vascular tone; high er doses (1 0-100 ,ug/kg) pro-
54 
duced a significant vasoconstriction of all vascular 
beds along with elevated blood pressure [8]. 
Since LX~ and LXB4 are products of activated 
leukocytes and LX~ primarily .of eosinophils [4] 
it is conceivable that they might contribute to car-
diovascular derangements which are mediated by 
activated leukocytes. Of special importance are 
vascular responses to acute anaphylaxis which are 
characterized by severe reduction of splanchnic 
organ blood flow due to blood vessel constriction 
[7]. In this respect, LX~ and LXB4 could act in 
concert with other mediators such as the 
leukotrienes. Therefore, blockade of the leuko-
triene action per se may not be sufficient to protect 
certain blood vessels unless LXA.a and LXB4 
blockers would be added. Further studies are 
necessary to confirm in vivo production of LXA-4 
and LXB4 in such situations by measurement of 
circulating Ievels of these lipoxins. Nevertheless, it 
is clear from the results of the present study that 
LX~ and LXB4 are bioactive compounds which 
produce responses of interest in vascular 
physiology. 
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